Literature DB >> 32669272

5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response.

Manish R Sharma1, Smita S Joshi2, Hedy L Kindler2.   

Abstract

Entities:  

Year:  2020        PMID： 32669272      PMCID： PMC7413824          DOI： 10.1158/1078-0432.CCR-20-1219

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  2 in total

1.  A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.

Authors:  Manish R Sharma; Smita S Joshi; Theodore G Karrison; Kenisha Allen; Grace Suh; Robert Marsh; Mark F Kozloff; Blase N Polite; Daniel V T Catenacci; Hedy L Kindler
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

2.  Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.

Authors:  Giuseppe Toffoli; Manish R Sharma; Elena Marangon; Bianca Posocco; Elizabeth Gray; Quan Mai; Angela Buonadonna; Blase N Polite; Gianmaria Miolo; Gianna Tabaro; Federico Innocenti
Journal:  Clin Cancer Res       Date:  2016-08-09       Impact factor: 12.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.